Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013587102> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W3013587102 abstract "Introduction: A number of different drugs have been developed to target the PI3 kinase/AKT/mTOR pathway. Most randomized trials in breast cancer have been performed in patients unselected for pathway activation although aberrations of components of this pathway are common. Here we explore the predictive value of PIK3CA and AKT mutations in randomized trials of drugs targeting this signaling route. Methods: We searched PubMed for randomized trials of drugs targeting the PI3 kinase/AKT/mTOR pathway in metastatic breast cancer. The search was supplemented by a manual search of recent ASCO and ESMO meetings. Eligible studies needed to report efficacy data based on presence or absence of PIK3CA or AKT status measured either in tumor specimens or in circulating DNA. Hazard ratios (HR) for progression-free survival (PFS) in PIK3CA or AKT mutant and wild-type groups were extracted and pooled in a meta-analysis using generic inverse variance and random effects modeling. Sensitivity analyses were performed based on the mechanism of action of the experimental drug. Results: Of the 15 studies identified, 10 studies comprising of 3615 patients were eligible for analysis. Studies included pan-PI3kinase inhibitors (n=5), alpha-specific PI3kinase inhibitors (n=1), AKT inhibitors (n=2) and mTOR inhibitors (n=2). Approximately 38% of patients had either PIK3CA or AKT mutations. The addition of drugs targeting the PI3 kinase/AKT/mTOR pathway was associated with a significantly longer improvement in PFS in patients with PIK3CA or AKT mutations than in those with wild-type status (HR 0.61, 95% CI 0.50-0.75 versus HR 0.83, 95% CI 0.67-1.02, p for difference = 0.04). Similar results were observed in sensitivity analyses (see Table). Conclusion: Benefit from drugs targeting the PI3 kinase/AKT/mTOR pathway in breast cancer appears to occur exclusively in those with PIK3CA or AKT mutations. Future trials of these drugs should be designed only in biomarker selected patients. Citation Format: Fahad A Almugbel, Ramy Saleh, Alberto Ocana, Atanasio Pandiella, Eitan Amir. PIK3CA status as a predictor of benefit from drugs targeting the PI3K/AKT/mTOR pathway: A meta-analysis of randomized trials [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P4-10-11." @default.
- W3013587102 created "2020-04-03" @default.
- W3013587102 creator A5022163984 @default.
- W3013587102 creator A5054881858 @default.
- W3013587102 creator A5054921200 @default.
- W3013587102 creator A5074810713 @default.
- W3013587102 creator A5079030791 @default.
- W3013587102 date "2020-02-14" @default.
- W3013587102 modified "2023-09-26" @default.
- W3013587102 title "Abstract P4-10-11: PIK3CA status as a predictor of benefit from drugs targeting the PI3K/AKT/mTOR pathway: A meta-analysis of randomized trials" @default.
- W3013587102 doi "https://doi.org/10.1158/1538-7445.sabcs19-p4-10-11" @default.
- W3013587102 hasPublicationYear "2020" @default.
- W3013587102 type Work @default.
- W3013587102 sameAs 3013587102 @default.
- W3013587102 citedByCount "0" @default.
- W3013587102 crossrefType "proceedings-article" @default.
- W3013587102 hasAuthorship W3013587102A5022163984 @default.
- W3013587102 hasAuthorship W3013587102A5054881858 @default.
- W3013587102 hasAuthorship W3013587102A5054921200 @default.
- W3013587102 hasAuthorship W3013587102A5074810713 @default.
- W3013587102 hasAuthorship W3013587102A5079030791 @default.
- W3013587102 hasConcept C11960822 @default.
- W3013587102 hasConcept C121608353 @default.
- W3013587102 hasConcept C126322002 @default.
- W3013587102 hasConcept C143998085 @default.
- W3013587102 hasConcept C168563851 @default.
- W3013587102 hasConcept C207103383 @default.
- W3013587102 hasConcept C44249647 @default.
- W3013587102 hasConcept C502942594 @default.
- W3013587102 hasConcept C530470458 @default.
- W3013587102 hasConcept C54355233 @default.
- W3013587102 hasConcept C60644358 @default.
- W3013587102 hasConcept C62478195 @default.
- W3013587102 hasConcept C71924100 @default.
- W3013587102 hasConcept C75217442 @default.
- W3013587102 hasConcept C86554907 @default.
- W3013587102 hasConcept C86803240 @default.
- W3013587102 hasConcept C98274493 @default.
- W3013587102 hasConceptScore W3013587102C11960822 @default.
- W3013587102 hasConceptScore W3013587102C121608353 @default.
- W3013587102 hasConceptScore W3013587102C126322002 @default.
- W3013587102 hasConceptScore W3013587102C143998085 @default.
- W3013587102 hasConceptScore W3013587102C168563851 @default.
- W3013587102 hasConceptScore W3013587102C207103383 @default.
- W3013587102 hasConceptScore W3013587102C44249647 @default.
- W3013587102 hasConceptScore W3013587102C502942594 @default.
- W3013587102 hasConceptScore W3013587102C530470458 @default.
- W3013587102 hasConceptScore W3013587102C54355233 @default.
- W3013587102 hasConceptScore W3013587102C60644358 @default.
- W3013587102 hasConceptScore W3013587102C62478195 @default.
- W3013587102 hasConceptScore W3013587102C71924100 @default.
- W3013587102 hasConceptScore W3013587102C75217442 @default.
- W3013587102 hasConceptScore W3013587102C86554907 @default.
- W3013587102 hasConceptScore W3013587102C86803240 @default.
- W3013587102 hasConceptScore W3013587102C98274493 @default.
- W3013587102 hasLocation W30135871021 @default.
- W3013587102 hasOpenAccess W3013587102 @default.
- W3013587102 hasPrimaryLocation W30135871021 @default.
- W3013587102 hasRelatedWork W11467293 @default.
- W3013587102 hasRelatedWork W12242190 @default.
- W3013587102 hasRelatedWork W12636511 @default.
- W3013587102 hasRelatedWork W14057612 @default.
- W3013587102 hasRelatedWork W14331536 @default.
- W3013587102 hasRelatedWork W14333088 @default.
- W3013587102 hasRelatedWork W16275066 @default.
- W3013587102 hasRelatedWork W16661828 @default.
- W3013587102 hasRelatedWork W4133181 @default.
- W3013587102 hasRelatedWork W718895 @default.
- W3013587102 isParatext "false" @default.
- W3013587102 isRetracted "false" @default.
- W3013587102 magId "3013587102" @default.
- W3013587102 workType "article" @default.